Latest 5-HT3 antagonist Stories
Among the most commonly used treatments for irritable bowel syndrome – which affects as many as 20 percent of the United States population – a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.
WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilmÂ® technology platform, in collaboration with APR Applied Pharma Research s.a.
CALIFON, NJ, July 6, 2011 /PRNewswire/ - PediatRx, Inc.
LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48 h)...
GRANISOL's co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients CALIFON, NJ, June 1, 2011 /PRNewswire/ - PediatRx, Inc.
Oncologists report that patient out-of-pocket costs can impact form of dosage CALIFON, NJ, May 5 /PRNewswire/ - PediatRx, Inc.
Fear of nausea a significant issue and often not discussed with healthcare providers CALIFON, NJ, April 25 /PRNewswire/ - PediatRx, Inc.
Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc.
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.